Oct 10, 2026 · 25 min

Biotech ETFs frame a week of company-specific moves

118 - End of Week Wrap up - Oct 9, 2026

The episode places coverage of Moderna, Caribou, and Lilly alongside broad market benchmarks to show how biotech performed during the week ending October 9.

3 key takeaways

1Major market indices provide the backdrop for the week’s biotech performance review.
2The wrap-up highlights Moderna, Caribou, and Lilly among the episode’s company-specific stories.
3Biotech-focused ETFs including XBI, ArcG, and IBB anchor the sector comparison.

Don't miss

The episode shifts from broad market benchmarks to company-level coverage of Moderna, Caribou, and Lilly.

The brief

Matthew Cloutier opens the October 9 end-of-week edition by setting up a review of major market indices, biotech benchmarks, and the sector stories that shaped the week.

The market frame includes SPX, Q's, and IWM, alongside biotech-focused funds XBI, ArcG, and IBB, giving the episode a broad-to-narrow view of performance.

Company coverage turns to Moderna and its MRNA ticker, Caribou, and Lilly, linking individual biotech stories to the wider market backdrop.

The episode’s central value is comparison: it treats biotech performance not as an isolated story, but as a sector movement measured against broader indices.

What was said on this episode

18 statements · 8 positive · 5 negative · 5 neutral

Matthew Cloutieron SPXPositive0:38
The SPX rose 1.16% during the week ending October 9.
“The SPX certainly had a great week this week, up 1.16%.”
Listen at 0:38
Matthew Cloutieron IWM and XBINegative0:48
IWM and XBI declined during the week ending October 9.
“We saw a decline in the small caps, IWM, as well as the XBI.”
Listen at 0:48
Matthew Cloutieron Bio-AI tradePositive2:24
The bio-AI trade may return to its prior extreme activity.
“there's some speculation that we're going to go back to craziness when it comes to the bio AI trade”
Listen at 2:24
Matthew Cloutieron CaribouNeutral4:39
Caribou pursued an allogeneic CAR-T method using donor-derived cells.
“Caribou Biosciences wanted to do was come up with an allogenic method.”
Listen at 4:39
Matthew Cloutieron CaribouNegative5:29
Caribou lacked a competitive differentiator versus other cell-therapy companies.
“Caribou really didn't have a differentiator that made them more competitive than these other companies.”
Listen at 5:29
Matthew Cloutieron Caribou Biosciences clinical programsNegative5:40
Caribou failed to attract sufficient investor support for its clinical strategy.
“they weren't able to get investors to buy into the concept”
Listen at 5:40
Matthew Cloutieron Caribou Biosciences leadershipPositive6:06
A more experienced CEO might have improved Caribou’s clinical trajectory.
“maybe if a ceo had been chosen that had a little bit more experience in the space it might have been helpful”
Listen at 6:06
Matthew Cloutieron CaribouNeutral6:57
Caribou reached a peak valuation of $1.8 billion in September 2021.
“they were at $1.8 billion in September of 2021”
Listen at 6:57
Matthew Cloutieron Eli Lilly MASH strategyPositive10:36
MASH could be an acquisition or expansion area for Lilly.
“an area where they might want to get into might be something like MASH”
Listen at 10:36
Matthew Cloutieron Viking TherapeuticsNegative11:37
Viking Therapeutics is not among Matthew Cloutier’s preferred Lilly acquisition candidates.
“it doesn't seem like Viking would be on my high list”
Listen at 11:37
Matthew Cloutieron ModernaPositive16:18
Moderna’s valuation rose from $25 billion to approximately $90 billion.
“they went from a 25 billion dollar valuation to about 60 billion immediately after and then now they're trading at about a 90 billion dollar valuation”
Listen at 16:18
Matthew Cloutieron Moderna melanoma drugNeutral16:41
Analysts estimate annual peak sales for Moderna’s melanoma drug below $3 billion.
“Some people are saying maybe $3 billion annually, probably not even that high”
Listen at 16:41
Matthew Cloutieron Moderna kidney cancer therapyNeutral18:33
Moderna is expected to present kidney-cancer therapy data in the first half of 2027.
“in H1 of 2027, they're going to be showing some data of a similar therapy in a kidney cancer indication”
Listen at 18:33
Matthew Cloutieron Moderna NSCLC programNegative19:09
Failure in Moderna’s NSCLC program could sharply reduce its valuation or market enthusiasm.
“a failure there could really help smack the company with reality”
Listen at 19:09
Matthew Cloutieron AbivaxPositive20:09
Abivax may be a better buy around the mid-$80s than at $140.
“I think maybe now that the stock has settled around the mid 80s or so, it's probably a better time to buy now than obviously when it was in 140.”
Listen at 20:09
Matthew Cloutieron Biotech M&ANeutral20:22
Biotech M&A processes generally take a long time and require patience.
“I think M&A takes a long time and you need to be patient with it.”
Listen at 20:22
Matthew Cloutieron InventivaPositive23:53
Inventiva is Matthew Cloutier’s next MASH investment candidate to investigate.
“I think the MASH play I'm going to look at next is IVA.”
Listen at 23:53
Matthew Cloutieron Inventiva pan-PPAR agonistPositive24:04
Inventiva’s pan-PPAR agonist has a good chance of succeeding in phase 3.
“I think it's got a good chance of succeeding in phase three”
Listen at 24:04

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.